Check for updates

#### **OPEN ACCESS**

EDITED BY Michael W. Best, University of Toronto Scarborough, Canada

#### REVIEWED BY

Hongzhen Fan, Beijing Huilongguan Hospital, Peking University, China Po-Han Chou, China Medical University, Taiwan

\*CORRESPONDENCE Bach Xuan Tran ⊠ bach.ipmph2@gmail.com

SPECIALTY SECTION This article was submitted to Schizophrenia, a section of the journal Frontiers in Psychiatry

RECEIVED 04 October 2022 ACCEPTED 05 January 2023 PUBLISHED 26 January 2023

#### CITATION

Tran BX, Nguyen TT, Boyer L, Fond G, Auquier P, Nguyen HSA, Tran HTN, Nguyen HM, Choi J, Le HT, Latkin CA, Nathan KI, Husain SF, McIntyre RS, Ho CSH, Zhang MWB and Ho RCM (2023) Differentiating people with schizophrenia from healthy controls in a developing Country: An evaluation of portable functional near infrared spectroscopy (fNIRS) as an adjunct diagnostic tool. *Front. Psychiatry* 14:1061284. doi: 10.3389/fpsyt.2023.1061284

#### COPYRIGHT

© 2023 Tran, Nguyen, Boyer, Fond, Auquier, Nguyen, Tran, Nguyen, Choi, Le, Latkin, Nathan, Husain, McIntyre, Ho, Zhang and Ho. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Differentiating people with schizophrenia from healthy controls in a developing Country: An evaluation of portable functional near infrared spectroscopy (fNIRS) as an adjunct diagnostic tool

Bach Xuan Tran<sup>1</sup>\*, Tham Thi Nguyen<sup>1</sup>, Laurent Boyer<sup>2</sup>, Guillaume Fond<sup>2</sup>, Pascal Auquier<sup>2</sup>, Hao Si Anh Nguyen<sup>3</sup>, Ha Thi Nhi Tran<sup>4</sup>, Hung Manh Nguyen<sup>5</sup>, Jongkwan Choi<sup>6</sup>, Huong Thi Le<sup>1</sup>, Carl A. Latkin<sup>7</sup>, Kalpana Isabel Nathan<sup>8</sup>, Syeda F. Husain<sup>9</sup>, Roger S. McIntyre<sup>10,11,12,13</sup>, Cyrus S. H. Ho<sup>14</sup>, Melvyn W. B. Zhang<sup>15</sup> and Roger C. M. Ho<sup>14,16</sup>

<sup>1</sup>Institute for Preventive Medicine and Public Health, Hanoi Medical University, Hanoi, Vietnam, <sup>2</sup>EA 3279, CEReSS, Research Centre on Health Services and Quality of Life, Aix Marseille University, Marseille, France, <sup>3</sup>Institute of Health Economics and Technology, Hanoi, Vietnam, <sup>4</sup>Hanoi Department of Health, Hanoi, Vietnam, <sup>5</sup>Mai Huong Daycare Psychiatric Hospital, Hanoi, Vietnam, <sup>6</sup>OBELAB, Inc., Seoul, Republic of Korea, <sup>7</sup>Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States, <sup>8</sup>Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States, <sup>9</sup>Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, <sup>10</sup>Mood Disorder Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>11</sup>Institute of Medical Science, University of Toronto, Toronto, ON, Canada, <sup>12</sup>Department of Psychiatry, University of Toronto, Toronto, ON, Canada, <sup>13</sup>Department of Pharmacology, University of Toronto, Toronto, ON, Canada, <sup>14</sup>Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, <sup>15</sup>Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang Technological University of Singapore, Singapore, Singapore, <sup>16</sup>Institute for Health Innovation and Technology, National University of Singapore, Si

**Introduction:** This study aimed to evaluate portable functional near-infrared spectroscopy (fNIRS) device as an adjunct diagnostic tool in Vietnam to assess hemodynamics when people with schizophrenia and healthy controls performed cognitive tasks.

**Methods:** One hundred fifty-seven participants were divided into schizophrenia (n = 110) and healthy controls group (n = 47), which were recruited by match of age, and gender. Hemodynamic responses in the frontal cortex were monitored with a 48-channel portable device during the Stroop Color-Word Test (SCWT) and Verbal Fluency Test (VFT). General linear model compared the differences in oxyhemoglobin (HbO<sub>2</sub>) levels between the two groups. The Receiver Operating Characteristic (ROC) graph was generated for each neuroanatomical area.

**Results:** People with schizophrenia did not show significant activation in the frontal lobe during the SCWT and VFT as compared to pre-task. During the VFT, the area under the ROC curve of the bilateral dorsolateral prefrontal cortex, bilateral orbitofrontal cortex, bilateral frontopolar prefrontal cortex, and bilateral ventrolateral prefrontal cortex were greater than 0.7 (p < 0.001). The area under the ROC curve

(AUC) for the right orbitofrontal cortex was maximal during the VFT (AUC = 0.802, 95%CI = 0.731–0.872). The Youden's index reached a peak (0.57) at the optimal cut-point value (HbO<sub>2</sub> cutoff <0.209  $\mu$ mol/ml for schizophrenia) in which the sensitivity was 85%; specificity was 72%; positive predictive value (PPV) was 0.88; negative predictive value (NPV) was 0.68 and correct classification rate was 76%.

**Discussion:** Assessing hemodynamics during VFT by portable fNIRS offers the potential as an adjunct diagnostic tool for schizophrenia in developing countries.

KEYWORDS

spectrometry, near-infrared, NIR spectroscopy, cortical hemodynamic response, schizophrenia, Vietnam

# 1. Introduction

Schizophrenia is a common psychiatric disorder that is characterized by positive symptoms including auditory hallucinations, thought interference, and delusion as well as negative symptoms including avolition, anhedonia, and blunted effect. The 1-year and lifetime prevalence of schizophrenia are 1 and 1.4%, respectively (1). The current diagnosis of schizophrenia is mainly based on clinical interviews, and structured clinical assessment according to Diagnostic Statistical Manual (DSM) or International Classification of Disease (ICD) (2). There is a need to require neuroimaging biomarkers to improve the objectivity and accuracy rate of diagnosis. According to Kraguljac et al. (3), the goal of developing diagnostic biomarkers is to detect the presence of the disease state of schizophrenia and to establish objective schizophrenia signatures. According to a recent review, the potential neuroimaging biomarker devices for schizophrenia include reduction of the cortical gray matter volume, dopamine hyperactivity, and hippocampal hyperactivity (3). Such biomarkers can only be detected by magnetic resonance imaging (MRI) and positron emission tomography (PET). The average fees of MRI and PET scans are approximately 1,400 USD and 5,700 USD, respectively, and require special imaging facilities. These neuroimaging methods pose a challenge to developing countries. Furthermore, people staying in rural areas do not have access to MRI and PET scans. There is a requirement to develop, apply, and validate portable function neuroimaging as an adjunct diagnostic tool for schizophrenia in developing countries.

Functional near-infrared spectroscopy (fNIRS) is a practical and cost-effective neuroimaging solution for developing countries. This device adopts a similar mechanism as functional MRI (fMRI) and utilizes infrared light to map brain activation based on assessing the changes in oxygenated, and deoxygenated hemoglobin, thus assessing the cerebral blood flow of each region (4). fNIRS was found to be significantly correlated with fMRI blood oxygen leveldependent (BOLD) signal regarding the respective neuroanatomical regions (5). This device also was found to have higher temporal resolution but lower spatial resolution than fMRI and PET (6). As compared to fMRI, the cost of fNIRS imaging is close to zero dollar per assessment, and the respondents can be measured in a sitting position rather than supine. The latest fNIRS device is portable (see Figure 1) and may be transported to rural areas. The validity of fNIRS to detect a psychiatric disorder and differentiate from other psychiatric disorders was investigated in major depressive disorders (7), bipolar disorders (8), and borderline personality disorders (9).

For fNIRS research in schizophrenia, Kumar et al. (10) reported a compensatory hyperactivation in the right frontopolar cortex in those with schizophrenia, which may stem from the underlying deficits in working memory. As those with schizophrenia were found to have a reduced profile of executive functions compared to healthy controls (11), cognitive tasks assessing executive function may differentiate people suffering from schizophrenia and healthy controls utilizing the fNIRS scan (12). Verbal fluency test (VFT) (13, 14) and Stroop Color-Word Test (SCWT) (15) are common neuropsychological paradigms to differentiate people with schizophrenia from healthy controls under fNIRS. The VFT was validated in non-English speaking Asian populations including Japanese (16, 17), Taiwanese (18, 19), and Chinese (20). Differences in performances during the VFT and SCWT were able to differentiate people with schizophrenia from other psychiatric illnesses (e.g., bipolar disorder) (21, 22).

This study aimed to validate the portable fNIRS device modality as an adjunct diagnostic and distinguishing tool for people with schizophrenia from healthy controls. The null hypothesis was that there were no differences in oxyhemoglobin (HbO<sub>2</sub>) concentration between patients with schizophrenia and healthy controls during the VFT and SCWT.

# 2. Materials and methods

## 2.1. Study setting and procedure

A cross-sectional study was conducted from September 2020 to June 2022 at three medical facilities, including (1) Institute for Preventive Medicine and Public Health; (2) Mai Huong Daycare Psychiatric hospital; and (3) National Psychiatric Hospital No. 1. After providing the informed consent, participants were required to complete questionnaires on demographics, assessed by Positive and Negative Symptoms Scale (PANSS), and undergo the fNIRS scan.

## 2.2. Sample size and participants

One hundred fifty-seven people with schizophrenia (n = 110, Age = 42.3  $\pm$  12.2 years, 39 females) and healthy controls (n = 47, Age = 40.2  $\pm$  11.1 years, 17 females) were recruited for this study. The two groups of participants were matched by age, and gender. People with schizophrenia who are independent diagnosed by a qualified psychiatrist at the Mai Huong Daytime Psychiatric Hospital



(40 patients), and National Psychiatric Hospital No1, Vietnam (70 patients) based on the ICD-10 diagnostic criteria (23). For healthy control group (47 participants), they were recruited from the community. After providing informed consent to participate in this study, they were invited to Institute for Preventive Medicine and Public Health, Hanoi Medical University to conduct a psychiatry screening test by the qualified psychiatrist. Particularly, the Brief Psychiatric Rating Scale (BPRS) was applied as a psychiatry screening test to recruit people into the healthy control group, and only people who were not suffering from any psychiatric disorders were recruited into this group and conducted fNIRS measurement.

Positive and negative symptoms of people with schizophrenia were evaluated by using the PANSS scale (24). The mean antipsychotic dose was calculated using olanzapine equivalence based on the World Health Organization's Collaborative Center for Drug Statistics Methodology. All antipsychotic doses were converted to 1 mg olanzapine equivalent (25). Exclusion criteria included: (i) intellectual disability, (ii) chronic medical diseases (e.g., cardiovascular, respiratory, liver, and kidney diseases), (iii) neurological disorders (e.g., stroke, Parkinson's disease, dementia), and (iv) substance use disorder. For healthy controls, they should not suffer from any psychiatric disorders.

## 2.3. Variables

Along with fNIRS measurement, information about demographic characteristics; and clinical characteristics (for patients with schizophrenia only) was also collected.

#### 2.3.1. Demographic characteristics included

Information about current age (years), gender (male/female), education level (secondary school or less/tertiary or higher) and family history of psychiatric disorders (yes/no).

# 2.3.2. Clinical characteristics (for patient group only)

Included information such as age of illness (years), duration of illness (years), duration of untreated illness (months), pharmacotherapy, and PANSS score.

Positive and negative syndrome scale is considered the bestvalidated instrument for schizophrenia based on three domains: Positive, Negative, and General psychopathology (26). After the clinical interview with PANSS scale, the psychiatrist can assess the presence and severity of positive symptoms, negative symptoms, as well as general psychopathology among schizophrenia patients. This scale consisted of 30 items, with seven items regarding positive symptoms, seven items regarding negative symptoms, and sixteen items regarding general psychopathology symptoms. For each item, a seven-point Likert scale is utilized to assess the symptom severity (27). Finally, the total score of each domain is summed, with a higher score indicating a higher severity.

## 2.4. Computerized cognitive tasks

#### 2.4.1. The computerized version of SCWT

J. R. Stroop introduced the Stroop test, which has become a standard method for assessing executive function, processing speed, cognitive flexibility, and selective attention (28, 29). The Stroop task's cognitive mechanism is related to selective attention, which requires the respondents to inhibit cognitive interference between ink color and word (30). Recently, the Stroop task has been used in several fNIRS studies, including studies for people with schizophrenia (22, 31, 32).

In this study, the E-prime software (Psychology Software Tools Inc.) displayed the Vietnamese computerized version of the SCWT and recorded the responses from participants. Five blocks comprised of three 30 s rest periods that alternated with two 30 s task periods (see **Figure 1**). Firstly, there were two rows of words that appeared in computer screen, with the words in the top row was a word in colored which was random in one of four colors, including "red," "blue," "yellow," and "green." The bottom row showed two different words and one of which was the color of the word in the top row and selected the answer from the remaining row. Before performing the test, participants rested for 30 s. Then the participants performed the task for 30 s. The total runtime to complete the SCWT was 125 s.

#### 2.4.2. The verbal fluency test (VFT)

The VFT was used to evaluate executive function, lexical access speed, and vocabulary (33). The VFT has been chosen from among the many neuropsychological tests utilized to detect neurocognitive deficits in people with major psychiatric disorders (34, 35) because this is an executive test with distinct differences in performance and neuroimaging data among types of major psychiatric disorders (36, 37). To date, several studies have utilized VFT on fNIRS measurement to investigate the differences in cortical activation patterns between people with psychiatric disorders and healthy controls (35, 38-40). The Vietnamese version of VFT was applied in this study, and this task included two main parts. During the first part (i.e., pre-task), respondents were asked to say "A," "B," "C," "D," and "E" continuously for 30 s by Vietnamese. For the next part (i.e., the VFT task), the respondents had 30 s to list as many items as possible under a random category (see Figure 2). The semantic fluency of Vietnamese was assessed. The total runtime was 185 s.

## 2.5. The fNIRS measurement

For the estimation of the  $HbO_2$  concentration, a portable fNIRS device (NIRSIT; OBELAB, Seoul, South Korea) with 48-channel and wavelengths 780 and 850 nm based on modified Beer–Lambert Law was utilized (41). This device included multi-distance source-detectors (24 dual-wavelength laser diodes and 32 photodetectors)



that were separated by a distance of 1.5 cm. Forty-eight positions corresponding to 48 regions of the prefrontal cortex were examined by the source-detector pairs (Figure 3). To eliminate motion artifact and machine drift of physical contamination, high and low pass filters were used, with a frequency range of 0.005-0.1 Hz and a threshold of signal noise set at 30 dB (42). The average level of hemodynamic activation from -5 to 0 s before cognitive test were used as the baseline measurement. The response data were recorded 8.138 times per second. Finally, the average level of HbO2 was calculated as the mean level of HbO2 changes over the total runtime for each cognitive test. As Figure 3, the fNIRS device with the 48 channels were divided into eight subregions (43, 44), including the dorsolateral prefrontal cortex (right side and left side); the ventrolateral prefrontal cortex (right side and left side); the frontopolar prefrontal cortex (right side and left side); and the orbitofrontal cortex (right side and left side), and the mean HbO2 concentration in each Brodmann region was calculated according to the respective channels.

### 2.6. Data analysis and statistical analyses

Data analysis and visualization were performed using Stata 15.0 (Stata Corporation), and NIRSIT Analysis Toolbox v3.6.2. (OBELAB Inc.). Descriptive data were generated for healthy controls and people with schizophrenia. To compare the proportion between two groups of participants, the Chi-square and Fisher's exact test were utilized. Differences in age between the healthy controls and people with schizophrenia were assessed by using the Wilcoxon rank-sum test (non-parametric method). The HbO2 levels between the rest period and task period were compared using the general linear model one level (GLM 1-Level) for healthy controls and people with schizophrenia. To compare the mean differences of HbO2 between the two groups, the general linear model two levels (GLM 2-Level) was utilized. The criterion for statistical significance was set at p < 0.05. We set contrast parameters between two among two groups, respectively, (healthy control vs. schizophrenia group). The one-way analysis of covariance (ANCOVA) was employed to compare mean HbO2 across these groups after adjusting for age, gender, and education.

In this study, the value of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were reported. Furthermore, the Receiver Operating Characteristic (ROC) curve and the area under the curve (AUC) are considered effective measures of accuracy has been explored with significant interpretations (45). This curve plays an important role in assessing the diagnostic ability of tests to distinguish the true state of individuals, determining the optimal cut-off values, and comparing two different diagnostic tests when they are performed on the same subject (45–47). In particular, ROC graphs were created based on the sensitivity and 1-specificity for all possible thresholds. In terms of AUC, rather than relying on a specific operational point, AUC summarizes the full position of the ROC curve (45,

48). The AUC is a useful and integrated measure of sensitivity and specificity that indicates the diagnostic test's inherent validity (37). Sensitivity and specificity were transformed to Youden's index (sensitivity + specificity-1) (49). Besides, AUC, PPV, and NPP, we selected the optimal cut-off point that maximized Youden's index.

## 3. Results

The demographic characteristics and some clinical characteristics of the respondents are showed in **Table 1**. No significant differences between people with schizophrenia and healthy controls in terms of age (p = 0.177), and gender (p = 0.932). The majority of participants was male (65.5%, for healthy control group, and 64.4% for people with schizophrenia) were found. Most people with schizophrenia reported that they did not have any family psychiatric history with 90.0%. The mean age of healthy controls was  $40.2 \pm 11.1$  years, while the mean age for schizophrenia was  $42.3 \pm 12.2$  years. For people with schizophrenia, the mean age of onset of illness, duration of treated illness and duration of untreated illness were  $27.6 \pm 8.2$  years,  $17.6 \pm 9.8$  years, and  $9.7 \pm 25.9$  months, respectively. The mean PANSS score was  $79.8 \pm 22.4$ , and the mean olanzapine equivalent dose for antipsychotic medications was  $13.0 \pm 7.1$  mg.

Figures 4, 5 present the activation maps of people with schizophrenia and healthy controls during the SCWT and VFT, respectively, [left side figure highlights the *T*-value distribution and right side figure indicates the neuroanatomical regions that show statistical significance with p < 0.05 (*T*-value > 1.96)]. People with schizophrenia did not show significant activation during the SCWT and VFT (p > 0.05). In contrast, health controls group showed a higher significantly activation during two cognitive tasks. In addition, the color map showed significant differences in HbO2 in the most regions of prefrontal brain region between people with schizophrenia and healthy controls during SCWT and VFT (p < 0.05).

**Table 2** shows that healthy controls had significantly higher level of HbO<sub>2</sub> change in the some regions of interest of the prefrontal cortex during the SCWT. The highest level of HbO2 in healthy controls was recorded at  $0.64 \pm 1.58$  in the left ventrolateral prefrontal cortex, while the lowest level of HbO2 concentration of people with schizophrenia was  $-0.24 \pm 1.34$  at the right orbitofrontal cortex. Furthermore, the difference in the level of HbO<sub>2</sub> concentration in the left ventrolateral prefrontal cortex (t = 2.32, p < 0.05) and left dorsolateral prefrontal cortex (t = 2.49, p < 0.05) between two groups was statistically significant.

**Table 3** shows that healthy controls had significantly higher level of HbO<sub>2</sub> change in all regions of interest of the prefrontal cortex during the VFT with p < 0.05. Particularly, the highest level of Oxy-Hb concentration of healthy controls was recorded at  $1.24 \pm 1.29$  in the left of orbitofrontal cortex, followed by the left ventrolateral prefrontal cortex ( $1.05 \pm 1.1.93$ ), and right ventrolateral prefrontal cortex ( $0.98 \pm 1.63$ ). For people with schizophrenia, the lowest level





Activation maps based on the general linear model (GLM) compare the HbO<sub>2</sub> levels during the rest period and Stroop Color-Word Test (SCWT) (A,B). Differences in HbO<sub>2</sub> levels during the SCWT are represented by colormap (C). Figures on the left indicate the *T*-value distribution and figures on the right highlight the neuroanatomical areas that show statistical significance with p < 0.05 (*T*-value > 1.96).

TABLE 1 Characteristics of participants (n = 157).

| Characteristics                          | Health    | Healthy controls |      | People with schizophrenia |         |
|--|-----------|------------------|------|---------------------------|---------|
|  | n         | %                | n    | %                         |         |
| Total                                    | 47        | 100.0            | 110  | 100.0                     |         |
| Gender                                   |           |                  |      |                           |         |
| Male                                     | 30        | 63.8             | 71   | 64.6                      | 0.932   |
| Female                                   | 17        | 36.2             | 39   | 35.5                      |         |
| Highest education level                  |           |                  |      |                           |         |
| Secondary school or less (grade < 12)    | 3         | 6.4              | 47   | 42.7                      | < 0.001 |
| High school or higher (grade $\geq 12$ ) | 44        | 93.6             | 63   | 57.3                      |         |
| Family psychiatric history               |           |                  |      |                           |         |
| No                                       | 47        | 100.0            | 99   | 90.0                      | 0.025   |
| Yes                                      | 0         | 0                | 11   | 10.0                      |         |
|  | Mean      | SD               | Mean | SD                        |         |
| Age                                      | 40.2      | 11.1             | 42.3 | 12.2                      | 0.177   |
| Age at illness onset (years)             | -         | _                | 27.6 | 8.2                       |         |
| Duration of treated illness (years)      | -         | -                | 17.6 | 9.8                       |         |
| Duration of untreated illness (months)   | -         | -                | 9.7  | 25.9                      |         |
| Olanzapine dose equivalent               | -         | _                | 13.0 | 7.1                       |         |
| Positive and negative syndrome scale     | e (PANSS) |                  |      |                           |         |
| Positive                                 |           |                  | 18.6 | 5.8                       |         |
| Negative                                 |           |                  | 19.4 | 6.3                       |         |
| General                                  |           |                  | 41.6 | 12.1                      |         |
| Total score of PANSS                     |           |                  | 79.8 | 22.4                      |         |

of Oxy-Hb was  $-0.54 \pm 1.70$  in the left ventrolateral prefrontal cortex, and  $-0.54 \pm 1.78$  in the right orbitofrontal cortex.

The area under the ROC curve (AUC) and asymptotic normal (95%CI) was estimated for each region during the SWCT and VFT (see **Figure 6** and **Tables 4**, 5). The value of AUC ranged from 0.575 to 0.657 during the SCWT and from 0.717 to 0.802 during the VFT. During the SCWT, the highest value of area under the ROC curve was recorded in the right orbitofrontal cortex with AUC = 0.657 (95%CI = 0.568–0.746), while the opposite finding was observed for the right ventrolateral prefrontal cortex with AUC = 0.562 (95%CI = 0.473–0.650). During the VFT, the AUC was greater than 0.7 (p < 0.001) in all regions of interest. In which, the highest level of AUC during VFT was 0.802 (AUC = 0.802, 95%CI = 0.731–0.872) in the right orbitofrontal cortex, followed by the right frontopolar prefrontal cortex (AUC = 0.751, 95%CI = 0.674–0.828) and left ventrolateral prefrontal cortex (AUC = 0.751, 95%CI = 0.666; 0.835).

For the region with highest the area under the ROC curve (right orbitofrontal cortex when performing VFT), the value of sensitivity, specificity, PPV, NPV, and optimal HbO<sub>2</sub> cut-off point was reported. In particularly, the highest level of Youden's index was reached at 0.57 with the optimal cut-point of level HbO2 value 0.209 (HbO<sub>2</sub> cut-off  $\geq$ 0.209 µmol/ml for healthy controls; HbO<sub>2</sub> cut-off <0.209 for people with schizophrenia) in which the sensitivity was 85%; specificity was 72%; PPV was 0.88; NPV was 0.68, and classification accuracy was 76% (Table 6).

## 4. Discussion

We found that fNIRS combined with neuropsychological tests succeeds in differentiating people with schizophrenia from healthy controls. The best schizophrenia diagnosis prediction was found for the combination of VFT and fNIRS with a focus on the right orbitofrontal cortex and a cutoff <0.209  $\mu$ mol/ml for schizophrenia (sensitivity was 85%; specificity was 72%; PPV was 0.88; NPV was 0.68 and classification accuracy was 76%). Our positive predictive value (88%) is comparable with previous fNIRS studies to differentiate schizophrenia from healthy controls (84.7-89.7%) (13, 14, 50-53). Our findings are in line with previous fNIRS research that found the prefrontal cortex, a key neuroanatomical area that demonstrates pathology in important psychiatric illnesses including schizophrenia (54, 55), major depressive disorder (56), bipolar disorder (8), generalized anxiety disorder (57), and borderline personality disorder (9). Furthermore, underdevelopment in the right orbitofrontal cortex may underlie vulnerability to psychosis and the core symptoms of schizophrenia (58). Particularly, the studies by Chou et al. (53) and Yang et al. (13) have indicated that the classification accuracy of fNIRS devices in distinguishing schizophrenia from healthy controls ranged from 68.2 to 79.7% and 66.5 to 85.0%, respectively. These differences in the classification accuracy of fNIRS devices might result from variations in the VFT's design. While the Japanese VFT or Chinese utilize syllabary, we chose Vietnamese alphabets. Actually, the lexical retrieval strategies of alphabetic and non-alphabetic languages differ (59). Therefore, it can affect cortical activity when performing this



highlights the neuroanatomical areas that show statistical significance with p < 0.05 (*T*-value > 1.96).

TABLE 2 The oxy-hemoglobin (Hbo2) levels changes between rest and task period in eight regions of interest of the prefrontal cortex during the Stroop Color-Word Test (SCWT) (mmol.mm) (n = 157).

| Regions of interest             | HC (Mean $\pm$ SD) | Schizophrenia (Mean $\pm$ SD) | <i>t</i> -value |  |  |  |
|---------------------------------|--------------------|-------------------------------|-----------------|--|--|--|
| Right side                      |                    |                               |                 |  |  |  |
| Ventrolateral prefrontal cortex | $0.35 \pm 1.35$    | $0.01 \pm 1.85$               | 1.32            |  |  |  |
| Dorsolateral prefrontal cortex  | $0.25\pm0.66$      | $0.03\pm0.99$                 | 0.84            |  |  |  |
| Frontopolar prefrontal cortex   | $0.34\pm0.69$      | $-0.04\pm0.91$                | 1.88            |  |  |  |
| Orbitofrontal cortex            | $0.33\pm0.70$      | $-0.24\pm1.34$                | 1.87            |  |  |  |
| Left side                       |                    |                               |                 |  |  |  |
| Ventrolateral prefrontal cortex | $0.64 \pm 1.58$    | $-0.14\pm1.12$                | 2.32*           |  |  |  |
| Dorsolateral prefrontal cortex  | $0.27\pm0.57$      | $-0.07\pm1.14$                | 2.49*           |  |  |  |
| Frontopolar prefrontal cortex   | $0.29\pm0.91$      | $-0.04 \pm 1.21$              | 0.63            |  |  |  |
| Orbitofrontal cortex            | $0.21\pm1.17$      | $-0.16\pm2.67$                | 0.34            |  |  |  |

(\*p < 0.05; HC, Health controls).

test. For example, at least two variations of Chinese VFT have been developed in fNIRS studies on people with schizophrenia, because they use different syllable systems (60). Specifically, the VFT developed by Li et al. (55) is applied to people in mainland China and differed from that used by Yang et al. (13) for residents in Taiwan. Executive function is a group of complex cognitive activities (e.g., working memory and impulse controls) that contributes to organizing, planning, and making decisions before conducting tasks. Executive impairment is one of the core pathological traits of schizophrenia. The VFT evaluates word production, executive TABLE 3 The oxy-hemoglobin (Hbo2) levels changes between rest and task period in eight regions of interest of the prefrontal cortex during the verbal fluency test (VFT) (mmol.mm) (*n* = 157).

| Regions of interest             | HC (Mean $\pm$ SD) | Schizophrenia (Mean $\pm$ SD) | t-value |  |  |  |  |
|---------------------------------|--------------------|-------------------------------|---------|--|--|--|--|
| Right side                      |                    |                               |         |  |  |  |  |
| Ventrolateral prefrontal cortex | $0.98 \pm 1.63$    | $-0.33\pm2.18$                | 2.66*   |  |  |  |  |
| Dorsolateral prefrontal cortex  | $0.78 \pm 1.11$    | $-0.15\pm1.47$                | 2.99*   |  |  |  |  |
| Frontopolar prefrontal cortex   | $0.79\pm0.85$      | $-0.01\pm0.97$                | 3.85*   |  |  |  |  |
| Orbitofrontal cortex            | $0.80\pm0.84$      | $-0.54\pm1.78$                | 2.60*   |  |  |  |  |
| Left side                       |                    |                               |         |  |  |  |  |
| Ventrolateral prefrontal cortex | $1.05\pm1.93$      | $-0.54\pm1.70$                | 3.48*   |  |  |  |  |
| Dorsolateral prefrontal cortex  | $0.55\pm0.94$      | $-0.14\pm1.21$                | 3.06*   |  |  |  |  |
| Frontopolar prefrontal cortex   | $0.79 \pm 1.50$    | $-0.32\pm1.16$                | 3.91*   |  |  |  |  |
| Orbitofrontal cortex            | $1.24\pm1.29$      | $-0.49\pm2.43$                | 2.92*   |  |  |  |  |

(\*p < 0.05; HC, Health controls).

TABLE 4 Performance of predicting the diagnosis of schizophrenia by portable functional near-infrared spectroscopy (fNIRS) during the Stroop Color-Word Test.

| Region of interest              | Right side |             |                 | Left side |             |                 |
|---------------------------------|------------|-------------|-----------------|-----------|-------------|-----------------|
|                                 | AUC        | 95% CI      | <i>p</i> -value | AUC       | 95% CI      | <i>p</i> -value |
| Ventrolateral prefrontal cortex | 0.558      | 0.466-0.650 | 0.217           | 0.646     | 0.553-0.737 | 0.002           |
| Dorsolateral prefrontal cortex  | 0.600      | 0.502-0.692 | 0.046           | 0.606     | 0.514-0.700 | 0.023           |
| Frontopolar prefrontal cortex   | 0.655      | 0.565-0.745 | <0.001          | 0.575     | 0.477-0.672 | 0.133           |
| Orbitofrontal cortex            | 0.657      | 0.568-0.746 | <0.001          | 0.582     | 0.491-0.672 | 0.077           |

AUC, area under receiver operating characteristic curve.

abilities, as well as cognitive flexibility (61). Before the development of fNIRS, the VFT was used to study cortical activation pattern of people with schizophrenia by functional magnetic resonance imaging (fMRI) (62). In this study, semantic fluency of Vietnamese language was assessed instead of phonemic fluency. Previous study found that schizophrenia was found to be associated with more compromises to the semantic fluency as compared to phonemic fluency (63). A recent meta-analysis found that the fNIRS-VFT paradigm enhances understanding, detection and differentiating various psychiatric conditions, and has the potential for developing cost-effective neuroimaging biomarkers for clinical psychiatry (64). Hence, it is not surprising that the VFT is a good neuropsychological test to distinguish hemodynamic activity between patients with schizophrenia and healthy controls by fNIRS measuring. A notable finding in the current study is the differences in HbO2 concentration between healthy group and schizophrenia group during the VFT, and this difference may be caused by underlying biological etiology and neuropathology. Our findings are consistent with previous functional neuroimaging studies. A fMRI study found that a specific medioprefronto-striato-thalamic functional dysconnectivity detected by VFT and implicated as the pathophysiology of schizophrenia (65). Furthermore, sigma non-opioid intracellular receptor 1 (SIGMAR1) gene polymorphism is involved in the pathogenesis of schizophrenia (66). People with schizophrenia who are Pro carriers for SIGMAR1 gene have significantly lower activation of the right pre-frontal cortex during the VFT as compared to healthy people who are homozygous for the Gln/Gln genotype (66).

Further fNIRS research is needed to evaluate other cognitive tests such as Wisconsin Card Sorting Test and working memory task



(e.g., N-back), which may be helpful in differentiating people with schizophrenia and healthy controls (67). fNIRS can be an objective tool to assess changes in brain hemodynamics after computerbased cognitive training in addition to improvement of scores in neuropsychological tests (68). A meta-analysis found that second TABLE 5 Performance of predicting the diagnosis of schizophrenia by portable functional near-infrared spectroscopy (fNIRS) during the verbal fluency test (VFT).

| Region of interest              | Right side |                    |         | Left side |             |                 |
|---------------------------------|------------|--------------------|---------|-----------|-------------|-----------------|
|                                 | AUC        | AUC 95% CI p-value |         | AUC       | 95% CI      | <i>p</i> -value |
| Ventrolateral prefrontal cortex | 0.717      | 0.634- 0.800       | <0.001  | 0.751     | 0.666-0.835 | <0.001          |
| Dorsolateral prefrontal cortex  | 0.740      | 0.656-0.823        | <0.001  | 0.725     | 0.636-0.814 | <0.001          |
| Frontopolar prefrontal cortex   | 0.751      | 0.674-0.828        | <0.001  | 0.724     | 0.632-0.815 | <0.001          |
| Orbitofrontal cortex            | 0.802      | 0.731-0.872        | < 0.001 | 0.747     | 0.672-0.821 | <0.001          |

AUC, area under receiver operating characteristic curve.

TABLE 6 The sensitivity, specificity, positive predictive, and negative predictive values (NPVs) of the HbO<sub>2</sub> cut-off point for differentiating healthy controls from schizophrenia patients at the right orbitofrontal cortex during the verbal fluency test (VFT).

| HbO <sub>2</sub> cut-off point (Unit: $\mu$ M) | Sensitivity | Specificity | Positive predictive<br>value | Negative predictive<br>value | Correctly classified | Youden's<br>index |
|--|-------------|-------------|------------------------------|------------------------------|----------------------|-------------------|
| 0.088  | 0.85        | 0.64        | 0.85                         | 0.65                         | 0.70                 | 0.49              |
| 0.102  | 0.85        | 0.65        | 0.85                         | 0.65                         | 0.71                 | 0.50              |
| 0.112  | 0.85        | 0.65        | 0.85                         | 0.66                         | 0.71                 | 0.51              |
| 0.121  | 0.85        | 0.66        | 0.85                         | 0.66                         | 0.72                 | 0.51              |
| 0.130  | 0.85        | 0.67        | 0.86                         | 0.67                         | 0.73                 | 0.52              |
| 0.136  | 0.85        | 0.68        | 0.86                         | 0.67                         | 0.73                 | 0.53              |
| 0.155  | 0.85        | 0.69        | 0.86                         | 0.67                         | 0.74                 | 0.54              |
| 0.169  | 0.85        | 0.70        | 0.87                         | 0.67                         | 0.75                 | 0.55              |
| 0.208  | 0.85        | 0.71        | 0.87                         | 0.67                         | 0.75                 | 0.56              |
| 0.209*   | 0.85        | 0.72        | 0.88                         | 0.68                         | 0.76                 | 0.57              |
| 0.212  | 0.83        | 0.72        | 0.88                         | 0.64                         | 0.75                 | 0.55              |
| 0.213  | 0.81        | 0.72        | 0.87                         | 0.62                         | 0.75                 | 0.53              |
| 0.250  | 0.79        | 0.72        | 0.87                         | 0.60                         | 0.74                 | 0.51              |
| 0.265  | 0.77        | 0.72        | 0.87                         | 0.57                         | 0.73                 | 0.48              |
| 0.280  | 0.74        | 0.72        | 0.86                         | 0.55                         | 0.73                 | 0.46              |
| 0.291  | 0.74        | 0.73        | 0.86                         | 0.55                         | 0.73                 | 0.47              |
| 0.300  | 0.72        | 0.73        | 0.86                         | 0.53                         | 0.73                 | 0.45              |
| 0.313  | 0.72        | 0.74        | 0.87                         | 0.54                         | 0.73                 | 0.46              |
| 0.317  | 0.70        | 0.74        | 0.87                         | 0.51                         | 0.73                 | 0.44              |

\*Optimal cut-off value of oxy-hemoglobin, <a>Optimal cut-off suggests healthy control;</a> <Optimal cut-off suggests the diagnosis of schizophrenia.

generation antipsychotics such as clozapine, olanzapine, quetiapine, and risperidone produce a mild remediation of cognitive deficits in schizophrenia (69). fNIRS can be applied and monitored the changes in brain hemodynamics after the initiation of antipsychotic treatment. Portable fNIRS scan may have the potential to assess cognitive function in people who are at ultra-high risk for schizophreniform psychosis and first-episode schizophrenia (70). A longitudinal study is required to assess the capability of portable fNIRS in predicting the diagnosis of schizophrenia in young people who present with early psychosis.

To improve classification accuracy of fNIRS device, future diagnostic methods should incorporate fNIRS and other biomarkers such as interleukin (IL)-8 and superoxide dismutase which were found to correlate with executive function in people with schizophrenia (71). As performances in VFT could differentiate people with the first episode of schizophrenia and healthy controls (72), monitoring hemodynamics when performing VFT by the

portable fNIRS scan could enhance the accuracy of diagnosis of the first episode of schizophrenia and allows early intervention.

This study has several limitations that should be considered when interpreting the finding, especially regarding the duration of illness, gender and clinical stage, and medication (73-76). Firstly, this is a cross-sectional study and a longitudinal study is needed to follow the changes in HbO2 concentration during the course of illness as well as the impact of antipsychotic medications on hemodynamic response when performing the cognitive tests. Secondly, fNIRS device in this study mainly assesses cortical regions and could not measure the changes of hemodynamics level of subcortical structures such as the cerebellum. Thirdly, because of the small sample, this study was not able to assess the hemodynamic activation of different types of schizophrenia as well as other characteristics such as age, gender and clinical stage of schizophrenia. Furthermore, this study lack results on behavioral performance during cognitive tests, and further study is required to explore this information for Vietnamese schizophrenia patients.

## Conclusion

In conclusion, this study indicates that during the VFT, the right orbitofrontal cortex is the most important neuroanatomical region to distinguish people with schizophrenia from healthy controls. The portable fNIRS device may be considered an adjunct diagnostic tool for schizophrenia.

# Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## **Ethics statement**

The studies involving human participants were reviewed and approved by the Vietnam Ministry of Health under Decision No 850/QD-BYT. The protocol of this study was approved by the Institutional Review Board of Hanoi Medical University (Number 58/ GCN-HDDNCYSH-DHYHN). The patients/participants provided their written informed consent to participate in this study.

## Author contributions

BT, HT, HL, CL, KN, RM, CH, and RH: conceptualization. TN, HT, HuN, and HaN: data curation. BT, TN, HaN, LB, GF, PA, SH, JC, RM, CH, CL, RH, and MZ: formal analysis. BT, TN, HT, RM, SH, JC, CH, CL, RH, and MZ: methodology. BT, TN, HaN, JC, and RH: software. BT, LB, GF, PA, HL, HT, HaN, RM, CH, CL, RH, and MZ: supervision. TN, HaN, HuN, and HT: investigation. BT, LB, GF, PA, HL, JC, RH, and MZ: writing—original draft. All authors contributed to the article, writing—review and editing, and approved the submitted version.

## Funding

This study received funding from the Gia Lam Urban Development and Investment Company Limited, Vingroup,

## References

1. Puri BH, Ho R. Revision Notes in Psychiatry. 3rd ed. New York, NY: CRC Press (2013).

2. Valle R. Schizophrenia in ICD-11: comparison of ICD-10 and DSM-5. Rev Psiquiatr Salud Ment. (2020) 13:95–104. doi: 10.1016/j.rpsmen.2020.01.002

3. Kraguljac N, McDonald W, Widge A, Rodriguez C, Tohen M, Nemeroff C. Neuroimaging biomarkers in schizophrenia. *Am J Psychiatry.* (2021) 178:509-21. doi: 10.1176/appi.ajp.2020.20030340

4. Ho C, Zhang M, Ho R. Optical topography in psychiatry: a chip off the old block or a new look beyond the mind-brain Frontiers? *Front Psychiatry*. (2016) 7:74. doi: 10.3389/fpsyt.2016.00074

5. Lai C, Ho C, Lim C, Ho R. Functional near-infrared spectroscopy in psychiatry. BJPsych Adv. (2017) 23:324–30. doi: 10.1192/apt.bp.115.015610

6. Kumar V, Shivakumar V, Chhabra H, Bose A, Venkatasubramanian G, Gangadhar B. Functional near infra-red spectroscopy (fNIRS) in schizophrenia:

Vingroup Innovation Foundation (VINIF) (Grant No. VINIF.2019.DA14), NUS Department of Psychological Medicine (R-177-000-100-001/R-177-000-003-001), and NUS iHeathtech Other Operating Expenses (R-722-000-004-731). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

## Acknowledgments

This study was managed by the Ministry of Health with Decision No. 850/QD-BYT, implemented by Institute for Preventive Medicine and Public Health, Hanoi Medical University, with funding from the Vingroup Innovation Fund under the agreement VINIF.2019.DA14. The authors would like to thank the VINGROUP, Ministry of Health, Hanoi Department of Health, Vietnam Young Physician Association, Hanoi Medical University, and the research collaborator.

# **Conflict of interest**

JC was employed by OBELAB, Inc. RM has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie and also a CEO of Braxia Scientific Corp.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

a review. Asian J Psychiatr. (2017) 27:18–31. doi: 10.1016/j.ajp.2017.0 2.009

7. Husain S, Yu R, Tang T, Tam W, Tran B, Quek T, et al. Validating a functional nearinfrared spectroscopy diagnostic paradigm for major depressive disorder. *Sci Rep.* (2020) 10:9740. doi: 10.1038/s41598-020-66784-2

8. Husain S, Tang T, Tam W, Tran B, Ho C, Ho R. Cortical haemodynamic response during the verbal fluency task in patients with bipolar disorder and borderline personality disorder: a preliminary functional near-infrared spectroscopy study. *BMC Psychiatry.* (2021) 21:201. doi: 10.1186/s12888-021-03195-1

9. Husain S, Tang T, Yu R, Tam W, Tran B, Quek T, et al. Cortical haemodynamic response measured by functional near infrared spectroscopy during a verbal fluency task in patients with major depression and borderline personality disorder. *EBioMedicine*. (2020) 51:102586. doi: 10.1016/j.ebiom.2019.1 1.047

10. Kumar V, Nichenmetla S, Chhabra H, Sreeraj V, Rao N, Kesavan M, et al. Prefrontal cortex activation during working memory task in schizophrenia: a fNIRS study. *Asian J Psychiatry.* (2021) 56:102507. doi: 10.1016/j.ajp.2020.102507

11. Tyburski E, Mak M, Samochowiec A, Plichta P, Bielecki M, Rek-Owodziń K, et al. The relationship between cingulum bundle integrity and different aspects of executive functions in chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* (2020) 102:109955. doi: 10.1016/j.pnpbp.2020.109955

12. Chou P, Huang C, Sun C. The potential role of functional near-infrared spectroscopy as clinical biomarkers in schizophrenia. *Curr Pharm Des.* (2020) 26:201–17. doi: 10.2174/13816128256666191014164511

13. Yang J, Ji X, Quan W, Liu Y, Wei B, Wu T. Classification of schizophrenia by functional connectivity strength using functional near infrared spectroscopy. *Front Neuroinform.* (2020) 14:40. doi: 10.3389/fninf.2020.00040

14. Ji X, Quan W, Yang L, Chen J, Wang J, Wu T. Classification of schizophrenia by seed-based functional connectivity using prefronto-temporal functional near infrared spectroscopy. *J Neurosci Methods.* (2020) 344:108874. doi: 10.1016/j.jneumeth.2020. 108874

15. Erdoğan S, Yükselen G. Four-class classification of neuropsychiatric disorders by use of functional near-infrared spectroscopy derived biomarkers. *Sensors (Basel).* (2022) 22:5407. doi: 10.3390/s22145407

16. Sumiyoshi C, Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, et al. Effect of orthography on the verbal fluency performance in schizophrenia: examination using Japanese patients. *Schizophr Res.* (2004) 69:15–22. doi: 10.1016/S0920-9964(03)00 174-9

17. Dan H, Dan I, Sano T, Kyutoku Y, Oguro K, Yokota H, et al. Language-specific cortical activation patterns for verbal fluency tasks in Japanese as assessed by multichannel functional near-infrared spectroscopy. *Brain Lang.* (2013) 126:208–16. doi: 10.1016/j. bandl.2013.05.007

18. Chou P, Lin W, Li W, Huang C, Sun C. Reduced language lateralization in first episode schizophrenia: a near infrared spectroscopy study. *Prog Neuro Psychopharmacol Biol Psychiatry*. (2017) 78:96–104. doi: 10.1016/j.pnpbp.2017.05.001

19. Chou P, Lin W, Hung C, Chang C, Li W, Lan T, et al. Perceived occupational stress is associated with decreased cortical activity of the prefrontal cortex: a multichannel near-infrared spectroscopy study. *Sci Rep.* (2016) 6:39089. doi: 10.1038/srep39089

20. Quan W, Wu T, Li Z, Wang Y, Dong W, Lv B. Reduced prefrontal activation during a verbal fluency task in Chinese-speaking patients with schizophrenia as measured by near-infrared spectroscopy. *Prog Neuropsychopharmacol Biol Psychiatry*. (2015) 58:51–8. doi: 10.1016/j.pnpbp.2014.12.005

21. Morrens M, Krabbendam L, Bak M, Delespaul P, Mengelers R, Sabbe B, et al. The relationship between cognitive dysfunction and stress sensitivity in schizophrenia: a replication study. *Soc Psychiatry Psychiatr Epidemiol.* (2007) 42:284–7. doi: 10.1007/s00127-007-0170-7

22. Aleksandrowicz A, Hagenmuller F, Haker H, Heekeren K, Theodoridou A, Walitza S, et al. Frontal brain activity in individuals at risk for schizophrenic psychosis and bipolar disorder during the emotional stroop task-an fNIRS study. *Neuroimage Clin.* (2020) 26:102232. doi: 10.1016/j.nicl.2020.102232

23. Jakobsen K, Frederiksen J, Hansen T, Jansson L, Parnas J, Werge T. Reliability of clinical ICD-10 schizophrenia diagnoses. *Nordic J Psychiatry*. (2005) 59:209–12. doi: 10.1080/08039480510027698

24. Kay S, Opler L, Lindenmayer J. Reliability and validity of the positive and negative syndrome scale for schizophrenics. *Psychiatry Res.* (1988) 23:99–110. doi: 10.1016/0165-1781(88)90038-8

25. Leucht S, Samara M, Heres S, Davis J. Dose equivalents for antipsychotic drugs: the DDD method. *Schizophr Bull.* (2016) 42(Suppl. 1):S90–4. doi: 10.1093/schbul/sbv167

26. Depp C, Loughran C, Vahia I, Molinari V. Assessing psychosis in acute and chronic mentally ill older adults. 2nd ed. In: Lichtenberg P editor. *Handbook of Assessment in Clinical Gerontology*. (San Diego, CA: Academic Press) (2010). p. 123–54. doi: 10.1016/ B978-0-12-374961-1.10005-3

27. Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull.* (1987) 13:261–76. doi: 10.1093/schbul/13.2.261

28. Stroop J. Studies of interference in serial verbal reactions. J Exp Psychol. (1935) 18:643. doi: 10.1037/h0054651

29. MacLeod C. Half a century of research on the stroop effect: an integrative review. *Psychol Bull.* (1991) 109:163. doi: 10.1037/0033-2909.109.2.163

30. Doan Q, Swerdlow N. Preliminary findings with a new Vietnamese stroop test. *Percept Motor Skills.* (1999) 89:173–82. doi: 10.2466/pms.1999.89.1.173

31. Hallak J, Machado-de-Sousa J, Crippa J, Sanches R, Trzesniak C, Chaves C, et al. Performance of schizophrenic patients in the stroop color word test and electrodermal responsiveness after acute administration of cannabidiol (CBD). *Braz J Psychiatry.* (2010) 32:56–61. doi: 10.1590/S1516-44462010000100011

32. Hepp H, Maier S, Hermle L, Spitzer M. The stroop effect in schizophrenic patients. *Schizophr Res.* (1996) 22:187–95. doi: 10.1016/S0920-9964(96)00080-1

33. Kempler D, Teng E, Dick M, Taussig I, Davis D. The effects of age, education, and ethnicity on verbal fluency. J Int Neuropsychol Soc. (1998) 4:531–8. doi: 10.1017/S1355617798466013

34. Takizawa R, Kasai K, Kawakubo Y, Marumo K, Kawasaki S, Yamasue H, et al. Reduced frontopolar activation during verbal fluency task in schizophrenia: a multichannel near-infrared spectroscopy study. *Schizophr Res.* (2008) 99:250–62. doi: 10.1016/ j.schres.2007.10.025

35. Takizawa R, Fukuda M, Kawasaki S, Kasai K, Mimura M, Pu S, et al. Neuroimagingaided differential diagnosis of the depressive state. *Neuroimage*. (2014) 85:498–507. doi: 10.1016/j.neuroimage.2013.05.126

36. Costafreda S, Fu C, Lee L, Everitt B, Brammer M, David AS. A systematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. *Hum Brain Mapp.* (2006) 27:799–810. doi: 10.1002/hbm.20221

37. Curtis V, Dixon T, Morris R, Bullmore E, Brammer M, Williams S, et al. Differential frontal activation in schizophrenia and bipolar illness during verbal fluency. J Affect Disord. (2001) 66:111–21. doi: 10.1016/S0165-0327(00)00240-8

38. Herrmann M, Ehlis A, Fallgatter A. Bilaterally reduced frontal activation during a verbal fluency task in depressed patients as measured by near-infrared spectroscopy. J Neuropsychiatry Clin Neurosci. (2004) 16:170–5. doi: 10.1176/jnp.16.2.170

39. Suto T, Fukuda M, Ito M, Uehara T, Mikuni M. Multichannel near-infrared spectroscopy in depression and schizophrenia: cognitive brain activation study. *Biol Psychiatry*. (2004) 55:501–11. doi: 10.1016/j.biopsych.2003.09.008

40. Koike S, Satomura Y, Kawasaki S, Nishimura Y, Takano Y, Iwashiro N, et al. Association between rostral prefrontal cortical activity and functional outcome in firstepisode psychosis: a longitudinal functional near-infrared spectroscopy study. *Schizophr Res.* (2016) 170:304–10. doi: 10.1016/j.schres.2016.01.003

41. Choi J, Kim J, Hwang G, Yang J, Choi M, Bae H. Time-divided spread-spectrum code-based 400 fW-detectable multichannel fNIRS IC for portable functional brain imaging. *IEEE J Solid State*. (2016) 51:484–95. doi: 10.1109/JSSC.2015.2504412

42. Khoe H, Low J, Wijerathne S, Ann L, Salgaonkar H, Lomanto D, et al. Use of prefrontal cortex activity as a measure of learning curve in surgical novices: results of a single blind randomised controlled trial. *Surg Endosc.* (2020) 34:5604–15. doi: 10.1007/s00464-019-07331-7

43. Dong S, Choi J, Park Y, Baik S, Jung M, Kim Y, et al. Prefrontal functional connectivity during the verbal fluency task in patients with major depressive disorder: a functional near-infrared spectroscopy study. *Front Psychiatry.* (2021) 12:659814. doi: 10.3389/fpsyt.2021.659814

44. Lee B, Choi J, Martin B. Roles of the prefrontal cortex in learning to time the onset of pre-existing motor programs. *PLoS One.* (2020) 15:e0241562. doi: 10.1371/journal.pone. 0241562

45. Hanley J, McNeil B. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology*. (1982) 143:29–36. doi: 10.1148/radiology.143.1. 7063747

46. Hanley J, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. *Radiology*. (1983) 148:839–43. doi: 10.1148/radiology.148.3.6878708

47. Kumar R, Indrayan A. Receiver operating characteristic (ROC) curve for medical researchers. *Indian Pediatr.* (2011) 48:277–87. doi: 10.1007/s13312-011-0055-4

48. Swets JA. ROC analysis applied to the evaluation of medical imaging techniques. *Invest Radiol.* (1979) 14:109–21. doi: 10.1097/00004424-197903000-00002

49. Youden W. Index for rating diagnostic tests. *Cancer*. (1950) 3:32–5. doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3

50. Einalou Z, Maghooli K, Setarehdan S, Akin A. Effective channels in classification and functional connectivity pattern of prefrontal cortex by functional near infrared spectroscopy signals. *Optik.* (2016) 127:3271–5. doi: 10.1016/j.ijleo.2015.12.090

51. Dadgostar M, Setarehdan S, Shahzadi S, Akin A. Classification of schizophrenia using SVM via fNIRS. *Biomed Eng Appl Basis Commun.* (2018) 30:1850008. doi: 10.4015/S1016237218500084

52. Xia D, Quan W, Wu T. Optimizing functional near-infrared spectroscopy (fNIRS) channels for schizophrenic identification during a verbal fluency task using metaheuristic algorithms. *Front Psychiatry*. (2022) 13:939411. doi: 10.3389/fpsyt.2022.939411

53. Chou P, Yao Y, Zheng R, Liou Y, Liu T, Lane H, et al. Deep neural network to differentiate brain activity between patients with first-episode schizophrenia and healthy individuals: a multi-channel near infrared spectroscopy study. *Front Psychiatry.* (2021) 12:655292. doi: 10.3389/fpsyt.2021.655292

54. Salgado-Pineda P, Radua J, Sarró S, Guerrero-Pedraza A, Salvador R, Pomarol-Clotet E, et al. Sensitivity and specificity of hypoactivations and failure of de-activation in schizophrenia. *Schizophr Res.* (2018) 201:224–30. doi: 10.1016/j.schres.2018.06.013

55. Li Z, Wang Y, Quan W, Wu T, Lv B. Evaluation of different classification methods for the diagnosis of schizophrenia based on functional near-infrared spectroscopy. *J Neurosci Methods*. (2015) 241:101–10. doi: 10.1016/j.jneumeth.2014.12.020

56. Husain S, Ong S, Cuizhen L, Tran B, Ho R, Ho C. Functional near-infrared spectroscopy during a decision-making task in patients with major depressive disorder. *Aust N J Psychiatry.* (2020) 55:485–93. doi: 10.1177/0004867420976856

57. Hu S, Li X, Law S, Shen C, Yao G, Zhang X, et al. Prefrontal cortex alterations in major depressive disorder, generalized anxiety disorder and their comorbidity during a verbal fluency task assessed by multi-channel near-infrared spectroscopy. *Psychiatry Res.* (2021) 306:114229. doi: 10.1016/j.psychres.2021.114229

58. Takahashi T, Nakamura M, Nishikawa Y, Komori Y, Nishiyama S, Takayanagi Y, et al. Potential role of orbitofrontal surface morphology on social and cognitive functions in high-risk subjects for psychosis and schizophrenia patients. *Psychiatry Res Neuroimaging*. (2019) 283:92–5. doi: 10.1016/j.pscychresns.2018.12.002

59. Eng N, Vonk J, Salzberger M, Yoo N. A cross-linguistic comparison of category and letter fluency: Mandarin and English. *Q J Exp Psychol.* (2019) 72:651–60. doi: 10.1177/1747021818765997

60. Chen P. Modern written Chinese in development. Lang Soc. (1993) 22:505–37. doi: 10.1017/S0047404500017450

61. Herrmann M, Horst A, Löble S, Möll M, Katzorke A, Polak T. Relevance of dorsolateral and frontotemporal cortex on the phonemic verbal fluency–a fNIRS-study. *Neuroscience.* (2017) 367:169–77. doi: 10.1016/j.neuroscience.2017.10.028

62. Weiss E, Hofer A, Golaszewski S, Siedentopf C, Brinkhoff C, Kremser C, et al. Brain activation patterns during a verbal fluency test-a functional MRI study in healthy volunteers and patients with schizophrenia. *Schizophr Res.* (2004) 70:287–91. doi: 10. 1016/j.schres.2004.01.010

63. Henry J, Crawford JR. A meta-analytic review of verbal. *Cogn Neuropsychiatry*. (2005) 10:1–33. doi: 10.1080/13546800344000309

64. Yeung M, Lin J. Probing depression, schizophrenia, and other psychiatric disorders using fNIRS and the verbal fluency test: a systematic review and meta-analysis. *J Psychiatr Res.* (2021) 140:416–35. doi: 10.1016/j.jpsychires.2021.06.015

65. Vandevelde A, Leroux E, Delcroix N, Dollfus S. Fronto-subcortical functional connectivity in patients with schizophrenia and bipolar disorder during a verbal fluency task. *World J Biol Psychiatry.* (2018) 19(Suppl. 3):S124–32. doi: 10.1080/15622975.2017. 1349339

66. Ohi K, Hashimoto R, Yasuda Y, Fukumoto M, Yamamori H, Umeda-Yano S, et al. The SIGMAR1 gene is associated with a risk of schizophrenia and activation of the prefrontal cortex. *Prog Neuropsychopharmacol Biol Psychiatry*. (2011) 35:1309–15. doi: 10.1016/j.pnpbp.2011.04.008

67. Palsetia D, Chandrasekhar K, Reddy M, De Sousa A, Karia S. Executive function in patients with schizophrenia based on socio-occupational impairment: a cross-sectional study. *Ind Psychiatry J.* (2018) 27:181–9. doi: 10.4103/ipj.ipj\_85\_18

68. Mak M, Tyburski E, Starkowska A, Karabanowicz E, Samochowiec A, Samochowiec J. The efficacy of computer-based cognitive training for executive dysfunction in schizophrenia. *Psychiatry Res.* (2019) 279:62–70. doi: 10.1016/j.psychres.2019.06.041

69. Woodward N, Purdon S, Meltzer H, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. *Int J Neuropsychopharmacol.* (2005) 8:457–72. doi: 10.1017/S146114570500516X

70. Hou C, Xiang Y, Wang Z, Everall I, Tang Y, Yang C, et al. Cognitive functioning in individuals at ultra-high risk for psychosis, first-degree relatives of patients with psychosis and patients with first-episode schizophrenia. *Schizophr Res.* (2016) 174:71–6. doi: 10.1016/j.schres.2016.04.034

71. Wu Z, Yu H, Wang X, Guan H, Xiu M, Zhang X. Interrelationships between oxidative stress, cytokines, and psychotic symptoms and executive functions in patients with chronic schizophrenia. *Psychosom Med.* (2021) 83:485–91. doi: 10.1097/PSY. 00000000000931

72. Giovannetti T, Goldstein R, Schullery M, Barr W, Bilder R. Category fluency in first-episode schizophrenia. J Int Neuropsychol Soc. (2003) 9:384–93. doi: 10.1017/S1355617703930049

73. Koike S, Takizawa R, Nishimura Y, Takano Y, Takayanagi Y, Kinou M, et al. Different hemodynamic response patterns in the prefrontal cortical sub-regions according to the clinical stages of psychosis. *Schizophr Res.* (2011) 132:54–61. doi: 10.1016/j.schres.2011. 07.014

74. Chou P, Koike S, Nishimura Y, Satomura Y, Kinoshita A, Takizawa R, et al. Similar age-related decline in cortical activity over frontotemporal regions in schizophrenia: a multichannel near-infrared spectroscopy study. *Schizophr Bull.* (2015) 41:268–79. doi: 10.1093/schbul/sbu086

75. Chou P, Koike S, Nishimura Y, Kawasaki S, Satomura Y, Kinoshita A, et al. Distinct effects of duration of untreated psychosis on brain cortical activities in different treatment phases of schizophrenia: a multi-channel near-infrared spectroscopy study. *Prog Neuro Psychopharmacol Biol Psychiatry*. (2014) 49:63–9. doi: 10.1016/j.pnpbp.2013.11.009

76. Chou P, Lin W, Lin C, Hou P, Li W, Hung C, et al. Duration of untreated psychosis and brain function during verbal fluency testing in first-episode schizophrenia: a near-infrared spectroscopy study. *Sci Rep.* (2015) 5:18069. doi: 10.1038/srep18069